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Background: Treatment of patients with pelvic adenoid cystic carcinoma (ACC) remains a 
challenge owing to the rarity of the disease, the lack of data, and the relative radioresistance 
of these tumors.
Case reports: This case series presents the results of three patients with recurrent or inoperable 
pelvic ACC treated with intensity-modulated radiotherapy (IMRT) plus carbon ion (C12) boost. 
Patients received C12 therapy at a dose of 3 Gray equivalents (GyE) (relative biological effective-
ness [RBE]) per fraction up to 24 GyE RBE, followed by 50 GyE of photon IMRT in 25 fractions.
Conclusion: IMRT plus C12 ion boost as a definitive or adjuvant treatment for pelvic ACCs 
seems to be a promising therapeutic option. No unexpected toxicity was detected and the observed 
toxicity remained consistently low. The initial treatment response is promising and similar to 
that experienced for head and neck ACCs.
Keywords: ACC of Bartholin’s gland, adenoid cystic carcinoma, ACC of the prostate, ion 
therapy, IMRT, tomotherapy, particle irradiation, carbon ion
Introduction
Given the rarity of pelvic adenoid cystic carcinomas (ACCs), there have been no pro-
spective trials to determine the optimal therapy for these tumors. ACCs are rare and 
comparatively chemoresistant and radioresistant tumors, located mainly in the head 
and neck area. They are the predominant histological type among malignancies of the 
minor salivary glands and the submandibular gland.1 Besides the head and neck area, 
they can arise from sites not associated with salivary tissues, such as breast,2 vulva,3 
cervix,4 and prostate.5 The World Health Organization (WHO) classification has com-
bined ACC of the prostate with other malignant basaloid tumors of the prostate under 
the single term basal cell carcinoma (BCC).6 Accordingly, there are only a few case 
reports of prostatic ACCs, with the largest series of 19 cases reported by Iczkowski 
et al.7 Most of these patients received radical surgery as first-line management, such 
as transurethral resection of the prostate, radical prostatectomy, or pelvic exenteratio.
In female patients, ACC of Bartholin’s gland is a rare malignancy of the vulva. So 
far, treatment with a wide local excision, with or without ipsilateral inguinal lymph-
adenectomy and with or without adjuvant radiotherapy,3,8–11 has been recommended as 
the optimal treatment. Adjuvant radiotherapy lowers the local recurrence in patients 
with positive resection margins.8 Furthermore, ACCs of Bartholin’s gland are likely 
to extend deeply into the lateral wall of the vagina and infiltrate the ischiorectal fossa. 
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Therefore, it may be difficult to remove the entire lesion, and 
patients with inoperable or gross residual disease remain a 
particular challenge.12
Independent of their origin, ACCs show aggressive local 
behavior with extensive infiltration, and they are character-
ized by multiple local relapses and a tendency for delayed 
recurrence and metastasis after initial treatment.8,13,14 It is 
postulated that the standard treatment for ACCs is radical 
surgical resection, ensuring free margins,13,15 but the extensive 
local infiltrative and perineural spread often causes difficulty 
in achieving high tumor control. Prognostic factors such as 
advanced tumors, positive resection margins, and perineural 
infiltration have been an indication for postoperative radio-
therapy, although most data are available only for head and 
neck ACCs.15–18 In the metastatic situation, case series of head 
and neck ACCs suggest that the median survival is about 
3 years, but some patients survive longer than 10 years.19,20 
Therefore, the potential toxicity of palliative treatment should 
be weighed against the fact that many patients have slowly 
progressive disease that can cause few symptoms for several 
years. Especially in the setting of inoperable, incompletely 
resected, or recurrent disease, treatment remains a therapeutic 
challenge. In advanced stages, conventional chemotherapy 
regimens are still used; however, few of these agents have 
shown efficacy.21,22 To date, the optimal treatment strategy 
for ACC outside the head and neck area remains unclear. 
Most data are limited to case reports owing to the rarity of 
the disease, which is further allocated to different medical 
specialties. Mutilating surgical procedures such as pelvic 
exenteration are often performed as a last option for these 
patients, since, so far, there is no valid treatment alternative.
Jensen et al showed that photon intensity-modulated 
radiotherapy (IMRT) plus a carbon ion (C12) boost for locally 
advanced inoperable or subtotally resected ACC in the head 
and neck resulted in significantly improved local control as 
well as overall survival compared to photon IMRT alone.23,24 
There was no significant difference between patients with 
inoperable and partially resected ACC.
Case reports
We report three cases of pelvic ACCs treated in accordance 
with the treatment given for head and neck ACCs, with IMRT 
plus C12 heavy ion boost, in a single institution between April 
2014 and March 2016.
Ethics
Written informed consent was obtained from all patients for 
publication of this case report and any accompanying images.
Treatment
According to the experiences with head and neck ACCs, we 
applied radiotherapy as photon IMRT plus C12 heavy ion 
boost as an individual treatment concept. We administered 
radiotherapy within a bimodal concept, consisting of a first 
phase of carbon ion irradiation (boost) to areas of mac-
roscopic residues or with an increased risk of recurrence, 
and a second phase of photon IMRT. The C12 treatment 
was performed at the Heidelberg Ion-Beam Therapy Center 
(Heidelberg, Germany) using the intensity-controlled raster-
scanned technique (active beam application, with one or two 
lateral beams). The first clinical target volume (CTV1) for 
the carbon ion boost included the macroscopic tumor and/or 
tumor bed. The first planning target volume (PTV1) consisted 
of a 3 mm margin around CTV1. Patients received 24 Gray 
equivalents (GyE) (relative biological effectiveness [RBE]) 
in 3 GyE (RBE) per fraction (five or six fractions per week). 
Doses were prescribed to the median PTV, which should be 
encompassed by the 95% prescription isodose. Organs at 
risk were contoured and adapted on the basis of computed 
tomography (CT) scans and magnetic resonance imaging 
(MRI). Dose constraints of normal tissue were respected 
according to QUANTEC reports.25,26
After the up-front C12 treatment, we performed pho-
ton IMRT of the pelvic lymphatic drainage. Patient 3 also 
received irradiation of the inguinal lymph drainage. CTV2 
included the macroscopic tumor or tumor bed and the lymph 
drainage. PTV2 consisted of a 3 mm margin around CTV2. 
IMRT was performed using a TomoTherapy® accelerator with 
6 MV photon beam up to 50 GyE using helical tomotherapy 
(Accuray, Sunnyvale, CA, USA) in 25 fractions (five frac-
tions per week) (Figure 1).
All patients were seen by a physician several times during 
radiation therapy and at regular follow-up intervals. MRI of 
the abdomen and pelvis was recommended every 2–3 months 
after irradiation. CT scans of the chest were recommended 
every 12 months. Treatment-related toxicity was documented 
according to the most up-to-date version of the Common 
Terminology Criteria for Adverse Events (CTCAE) v4.0 
classification.27
Case 1
Case presentation
We present the case of a 65-year-old Caucasian male 
( Karnofsky performance status [KPS] 80%) who was initially 
diagnosed with prostate cancer in March 2012 at another 
institution. Prostate-specific antigen (PSA) levels were ele-
vated and biopsy of the prostate showed an  adenocarcinoma 
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with a Gleason score of 6. A CT scan of the pelvis revealed a 
synchronous small tumor of the perirectal soft tissue infiltrat-
ing the rectum and the pelvic floor. The patient underwent 
radical prostatectomy and a biopsy of the second tumor 
site was taken during this surgery. The prostatic cancer was 
diagnosed as a pT2c, pN0, L0, V0, R0 adenocarcinoma of 
the prostate. Pathological examination of the second tumor 
reportedly revealed histological characteristics of a tumor 
with “basal cell carcinoma patterns.” No further treatment 
was initiated until, in February 2014, a CT scan showed a 
local progression of the pelvic tumor. The patient underwent 
rebiopsy and pathological reexamination of the first biopsy. 
Based on these findings, a diagnosis of ACC of the pelvic 
floor was established. Histologically, the tumor did not origi-
nate from the prostate and was not infiltrating the prostate.
The patient presented at our institution in March 2014. 
2-Fluoro-2-deoxy-D-glucose positron emission tomography/
CT showed accumulations in the pelvic floor and perirectal soft 
tissue as a sign of a locally advanced and aggressive tumor. 
Furthermore, a solitary bone metastasis was diagnosed in the 
left ischium. Surgical options were limited and the only rea-
sonable approach seemed to be pelvic exenteration, which the 
patient refused (Figure 2A). Therefore, definitive IMRT plus 
C12 heavy ion boost was applied as an individual treatment.
Treatment was tolerated with moderate acute and late 
toxicity. During radiotherapy, the patient had mild diarrhea 
Figure 1 Dose distribution and dose–volume histogram of boost plans with a carbon ion total dose of 24 GyE (RBE); isodoses in percent. (A) Case 1; (B) case 2; (C) case 3.
Abbreviations: RBE, relative biological effectiveness; GyE, Gray equivalents.
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(common toxicity criteria [CTC] grade 1) and acute urinary 
retention requiring catheterization. The patient already had 
urinary incontinence (CTC grade 2–3) before radiotherapy, 
and this did not worsen during radiotherapy. At the end of 
treatment, the skin in the radiation field showed an erythema 
(CTC grade 1). Furthermore, he had mild pain in the ischium, 
which was located in the irradiation field.
Outcome and follow-up
The patient still had urinary incontinence and mild pain in the 
ischium. Stools and defecation were normal after radiother-
apy (Figure 2B). In September 2015, 16 months after treat-
ment, MRI scans revealed a progression of the initial tumor 
region in the pelvic floor with an infiltration of the rectum 
but no further signs of pathological lymph nodes. PSA levels 
were not elevated. After multidisciplinary consultation and 
with the patient’s consent, pelvic exenteration was performed. 
A pathological evaluation established a diagnosis of BCC 
with ACC-like patterns. The carcinoma showed p63-positive 
basaloid cells with high expression of BCL2 and EGFR. 
There was no expression of chromogranin A, synaptophysin, 
or alpha-methylacyl-CoA racemase, or translocation of 6q23. 
Slightly positive immunostaining for p63 and expression of 
androgen receptors were found in about 80% of the cells. 
Ki67 staining was 10%. A CT scan of the chest taken at this 
time showed multiple small pulmonary nodes.
In February 2016, an MRI scan of the pelvis showed a 
residual and stable bone metastasis in the ischium but no 
further signs of tumor progression or recurrence. A follow-up 
CT scan of the chest revealed a slowly growing pulmonary 
metastasis. Chemotherapy with gemcitabine and carboplatin 
was initiated at another hospital.
Case 2
Case presentation
We further present the case of a 44-year-old Caucasian male 
(KPS 90%) with an ACC of the pelvic floor and the perineum, 
who was first seen in our department in July 2015.
The patient had been well until 2 years before this pre-
sentation, when he noted perirectal pain. In May 2015, the 
patient presented at another university hospital for evaluation 
after the pain level increased. In the clinical examination, 
a rigidification was found in the perineal area. PSA levels 
were within the normal range. Pathological examination 
disclosed an ACC. CT and MRI of the chest, abdomen, and 
pelvis revealed a tumor of the perineum which was infiltrat-
ing the penile cavernous body and the prostate (Figure 2C). 
No pathological pelvic lymph nodes were found. Similarly 
Figure 2 (A) Pretreatment MRI (T1_tra), case 1; (B) follow-up MRI (T1_tra) 6 weeks after treatment, case 1; (C) pretreatment MRI (T1_dixon_tra), case 2; (D) follow-up 
MRI (T1_tra) 5 months after treatment, case 2. Arrows indicate primary tumor.
Abbreviation: MRI, magnetic resonance imaging.
A C
B D
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to our first case, treatment options were limited to surgery 
and would be mutilating for the patient. After multidisci-
plinary consultation, we performed bimodal radiotherapy 
as described in the “Treatment” section.
During radiotherapy from July to September 2015, the 
patient had dysuria (CTC grade 2), pollakiuria (CTC grade 1), 
and worsening of the perineal swelling, with perirectal pain 
and pain during defecation. At the end of treatment, he had an 
erythema (CTC grade 2) in the radiation field with no signs 
of desquamation. Virility, stools, and defecation were normal.
Outcome and follow-up
Six weeks after radiotherapy, all symptoms including the 
perirectal pain had decreased. The patient still had mild 
pollakiuria. Virility, stools, and defecation were normal after 
radiotherapy, while the KPS was 80%. MRI scans showed a 
partial remission with residual contrast enhancement in the 
pelvic floor (Figure 2D), the cavernous body, and the prostate, 
and no signs of progression. We continued the follow-up 
every 3 months. At the latest follow-up, 24 months after ion 
therapy, there were no new pathological findings.
Case 3
Case presentation
A 50-year-old female (KPS 90%) presented at our institution in 
January 2015 with a diagnosis of a recurrent ACC of Bartholin’s 
gland. Initially, the patient had been diagnosed in 2011 at another 
institution after presenting with a painless, gradually increas-
ing vulvar mass. Hemivulvectomy with unilateral superficial 
and deep inguinal lymph-node dissection was performed and 
revealed a pT1, pN0 (0/14), R0, L0, V0, M0 ACC of Bartholin’s 
gland. Four years later, in August 2015, she presented with a 
5 cm diameter recurrence in the same region but now also infil-
trating the pelvic floor. A second local excision was performed 
but the resection was judged to be macroscopically incomplete, 
which was confirmed by the pathological findings. Postoperative 
MRI scans showed a residual tumor infiltrating the pelvic floor, 
the lateral vaginal wall, and the levator ani muscle. No suspect 
lymph nodes or distant metastases were found.
During radiotherapy from January 2016 to March 2016, 
the patient had dysuria and pollakiuria. At the end of treatment, 
the skin in the radiation field showed a mild erythema (CTC 
grade 2) with moist vaginal and inguinal desquamation. The 
patient had diarrhea (CTC grade 1) with no need for medication.
Outcome and follow-up
Six weeks after radiotherapy, the patient was in good con-
dition (KPS 80%) and all symptoms including the moist 
 desquamation had decreased. She still had tolerable vaginal 
pain. Stools and defecation have been normal since radiother-
apy. The patient was provided with a vaginal dilator kit and 
instructed to use the dilator three or four times per week to 
avoid vaginal stenosis. MRI scans showed a partial remission 
with a residual contrast enhancement in the pelvic floor and 
no signs of progression. We continued the follow-up every 
3 months. The latest follow-up, 16 months after ion therapy, 
did not reveal any new pathological findings.
Conclusion
For all of the presented patients, the alternative to bimodality 
treatment would have been a mutilating pelvic exenteration, 
potentially not very efficient chemotherapy, or best support-
ive care. All patients were relatively young and had a good 
performance status. Therefore, the preservation of quality of 
life was extremely important. Notably, patients in this report 
tolerated therapy well with the use of bimodality treatment 
and dose delivery up to 24 GyE C12 plus 50 GyE photons. 
No unexpected toxicity was detected and the observed toxic-
ity remained consistently low. The most significant adverse 
effect was an acute urinary retention and an erythema (CTC 
grade 2) with moist desquamation.
Considering the extensive and mutilating surgical proce-
dures used, definitive, adjuvant, or postoperative radiotherapy 
using our new approach offers a treatment alternative to 
patients with pelvic ACC, especially for those with locally 
advanced disease. Owing to the multiple local recurrences 
seen in ACCs, some authors postulate that radiation probably 
delays rather than prevents recurrences. However, from our 
point of view, delaying a morbid surgical procedure is to be 
considered as a positive treatment outcome in terms of qual-
ity of life. The initial treatment response is promising and 
similar to our experience for head and neck ACCs, although 
longer follow-up is needed to assess local control. ACCs of 
the pelvis are likely to recur locally by extensive infiltration 
of the pelvic floor, the skeletal pelvis, and the lateral pelvic 
wall, which should be considered in treatment planning and 
target definition. Because of the limited number of patients 
treated, additional data and longer follow-up will be required 
to validate the efficacy of this approach. However, our initial 
findings suggest that the use of C12 therapy followed by 
photon IMRT may be considered for patients with locally 
advanced pelvic ACC.
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